Qiming Venture Partners has led a significant financing round for Sany Hydrogen Energy, underscoring confidence in the company's capabilities and commitment to advancing green hydrogen solutions in a rapidly evolving energy landscape.
Target Company Overview
Jiangsu Tiga Medical Co., Ltd. (300347.SZ, 03347.HK), an investment of Qiming Venture Partners, has achieved the highest AAA rating in the latest Environmental, Social, and Governance (ESG) ratings published by Morgan Stanley Capital International (MSCI). This notable accomplishment marks the company's inaugural receipt of the top ESG rating from MSCI, positioning it among the global leaders in ESG practices and establishing it as a benchmark enterprise in its industry.
Tiga Medical has recently validated its greenhouse gas reduction targets through the Science-Based Targets initiative (SBTi). The company actively fulfills its environmental responsibilities by enhancing its environmental management system, strengthening emissions and resource use management, and implementing digital platforms and green office practices. In terms of social responsibility, Tiga Medical promotes digital transformation, employing AI technology to optimize clinical trial processes, safeguarding women's employee rights, and setting diversity targets. The company engages in various philanthropic initiatives through the Hangzhou Tiga Medical Public Welfare Foundation, which focuses on supporting medical, education, and poverty alleviation efforts and contributes to rural revitalization.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
The healthcare and life sciences sector in China is rapidly evolving, driven by increasing demand for innovative medical solutions and advancements in technology. With a growing aging population and a rise in chronic diseases, the need f
Similar Deals
Dingfeng BioCapital and Innovation Works → Heranova Lifesciences Holding
2023
Adicon Holdings Limited → Crown Bioscience Inc.
2026
启明创投
invested in
蔚程医药有限公司
in 2025
in a Seed Stage deal
Disclosed details
Transaction Size: $142M